News|Articles|May 16, 2016

FDA Warns of Serious Side Effects Associated with Fluoroquinolone Drugs

FDA is advising there may be serious and potentially permanent side effects associated with taking fluoroquinolone antibacterial drugs consistently.

FDA is advising that the serious side effects associated with fluoroquinolone antibacterial drugs may outweigh the benefits for patients with sinusitis, bronchitis, and uncomplicated urinary tract infections, the agency said in a May 12, 2016 safety announcement. FDA says treatment with fluoroquinolone should be reserved for those with no alternative treatment options. An FDA safety review of the drugs has shown that, when used consistently, fluoroquinolones may be associated with disabling, and potentially permanent side effects involving the tendons, muscles, joints, nerves, and central nervous system.

FDA will now require fluoroquinolone’s labels be updated with the new safety information, the agency said in a safety announcement. FDA previously released safety warnings about the safety of fluoroquinolones in 2008 and 2013. In July 2008, FDA warned that patients taking fluoroquinolones may be at an increased risk for tendinitis and tendon rupture. The agency released an additional statement in August 2013, saying that the fluoroquinolones may cause peripheral neuropathy, or severe, potentially permanent, nerve damage.

Source: FDA
 


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.